Viatris Is Name of New Company Formed from Merger of Mylan and Pfizer’s Generics BizBy
Mylan and Pfizer have announced Viatris as the name of the new company to be formed by the planned combination of Mylan and Upjohn, Pfizer’s off-patent branded and generic established medicines business, which was announced earlier this year (August 2019).
In August 2019, Mylan and Pfizer agreed to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, to form a new pharmaceutical company. The new name will be effective upon closing of the combination, which is expected to occur in mid-2020. The two companies will continue to operate as independent, separate organizations until close. The new company would have pro forma 2020 revenues of $19 billion to $20 billion.
It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn. The companies say that further information regarding Viatris, including the company’s full executive management team, board of directors, stock symbol, and logo will be available at a later date.